Why Ibex Stock Crushed it on Friday

Ibex reported fiscal Q4 revenue of just over $164 million, up nearly 12% year over year and above the roughly $153 million analyst consensus, while adjusted EPS of $0.85 beat the $0.79 estimate. Healthcare technology revenue rose 42%, helping deliver the company’s sixth consecutive quarter of double-digit growth. For fiscal 2027, management guided to $700 million-$715 million in revenue and $90 million-$94 million in adjusted EBITDA, with both low ends implying at least 9% growth; shares rose nearly 7% Friday.

Analysis

The key underwriting issue is conversion, not top-line momentum. Adjusted profit growth lagging revenue implies that wage inflation, delivery mix, onboarding expense, or reinvestment is absorbing operating leverage; the new-year EBITDA framework appears to preserve rather than expand margin. For IBEX to sustain a multiple re-rating over the next 1-3 months, management needs to demonstrate that healthcare-tech wins carry higher lifetime value and that utilization improves after initial client ramp costs.

Relative to CX/BPO peers Concentrix (CNXC), TaskUs (TASK), TTEC and Teleperformance (TLPFY), IBEX has a plausible share-gain narrative in higher-complexity, regulated programs where AI is more likely to augment agents than fully replace them. The second-order risk is that rapid adoption of generative AI by large enterprise clients compresses per-contact pricing before IBEX can retain enough of the productivity savings; smaller providers also face greater client-concentration and contract-renewal volatility than diversified incumbents.

Do not chase a post-results move without liquidity, valuation, net-leverage and top-client exposure data. The immediate catalyst is likely limited to follow-through buying and estimate revisions; the more investable 6-18 month catalyst is evidence of EBITDA-margin expansion despite AI-related pricing pressure. A miss to the EBITDA range, slowing healthcare-tech growth, or a material client-loss disclosure would invalidate the share-gain thesis quickly.

Key Decisions for Investors

• Keep IBEX on a buy-on-pullback watchlist rather than initiating into momentum; consider entry only after confirming net leverage, average daily dollar volume, and whether the largest client represents less than 15% of revenue. Target a 10-15% pullback or evidence of two consecutive quarters of margin expansion.
• If liquidity supports institutional execution, structure a 3-6 month pair: long IBEX / short CNXC in equal beta-adjusted dollars. The thesis is that IBEX’s higher-growth vertical mix can drive relative estimate revisions; exit if IBEX’s EBITDA-margin trajectory remains flat or CNXC delivers superior organic-growth acceleration.
• Monitor quarterly revenue-per-agent, attrition, offshore/onshore mix, and contract pricing. An EBITDA outcome near the low end of management’s range despite revenue near the high end would signal unfavorable mix and should trigger a short-bias reassessment rather than averaging into a long.
• Avoid using NFLX or NVDA as read-through trades; their inclusion has no operating linkage to IBEX and should not influence positioning.